Cornercap Investment Counsel Inc. Has $1.95 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Cornercap Investment Counsel Inc. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,316 shares of the medical equipment provider’s stock after selling 491 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Hologic were worth $1,954,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV raised its stake in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares in the last quarter. Graypoint LLC raised its position in Hologic by 3.9% during the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after acquiring an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after acquiring an additional 165 shares during the last quarter. Parallel Advisors LLC grew its position in Hologic by 11.5% in the fourth quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 189 shares in the last quarter. Finally, Brown Advisory Inc. increased its stake in shares of Hologic by 0.3% during the 4th quarter. Brown Advisory Inc. now owns 74,438 shares of the medical equipment provider’s stock worth $5,319,000 after purchasing an additional 192 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Stephens reiterated an “overweight” rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a research note on Friday, August 16th. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Finally, StockNews.com raised shares of Hologic from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Price Performance

NASDAQ:HOLX opened at $80.01 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The company has a fifty day moving average price of $79.92 and a 200 day moving average price of $76.76. The stock has a market cap of $18.67 billion, a P/E ratio of 40.82, a PEG ratio of 2.58 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the firm posted $0.93 EPS. The business’s revenue was up 2.7% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.